ImmPACT Bio Announces California-Based GMP Facility for Clinical Production of IMPT-314, a CD19/CD20 CAR T Therapy for B-Cell Malignancies and Autoimmune Diseases

ImmPACT Bio Announces California-Based GMP Facility for Clinical Production of IMPT-314, a CD19/CD20 CAR T Therapy for B-Cell Malignancies and Autoimmune Diseases
Biomerics, the leading vertically integrated contract manufacturer for the interventional medical device market, announced today that it has entered into definitive agreements to merge with Precision Concepts’ medical business (“Precision Concepts Medical”).
UL Solutions, a global leader in applied safety science, announced today that it plans to open a new battery testing laboratory in Auburn Hills, Michigan, in mid-2024
Pfizer Inc. has planned a $120 million investment at its Kalamazoo manufacturing facility to support the production of its COVID-19 antiviral treatment, Paxlovid.
Engineered to meet unique automation needs across various industries, Epson Robots, the #1 SCARA robot manufacturer in the world, today announced the new GX Series robot lineup with the GX4 and GX8.
The new Biomerics office will be equipped with multiple balloon-forming machines, state-of-the-art test equipment, and a cleanroom that is ISO 13485:2016 certified.
Stellantis N.V. and Samsung SDI announced that they have executed binding, definitive agreements to establish an electric-vehicle battery manufacturing facility in Kokomo, Indiana.
Through this investment, the Sligo site will feature Class 7 cleanroom manufacturing environments and state-of-the art thermoforming operations, fully certified to ISO 13485 standards and meeting the highest regulatory requirements.
The Swedish electric vehicle battery manufacturer says it will construct a major new production facility in the city of Heide near Germany’s North Sea coastline.
Celerion, a clinical research organization (CRO) to the biopharmaceutical industry, has announced completion of additions to its research capacity and services
CARsgen Therapeutics 37,000-ft facility for clinical and early-stage commercial manufacturing was designed and built in just 12 months.
The CGMP facility represents a critical first step in a new era of drug manufacturing aimed at strengthening domestic supply chain resiliency